The US and the EU both posted impressive numbers of novel approvals in the first half of 2021, but with little overlap.
Only three of the 32 new molecular entities and novel biologics authorized by the US Food and Drug Administration had...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?